TITLE

US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles

AUTHOR(S)
Galetta, Steven L.; Markowitz, Clyde
PUB. DATE
February 2005
SOURCE
CNS Drugs;2005, Vol. 19 Issue 3, p239
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Several disease-modifying agents (DMAs) are approved for the treatment of multiple sclerosis, including three interferon (IFN)-beta products, glatiramer acetate and mitoxantrone. This article reviews the adverse event profiles of these DMAs based on the pivotal phase III trials, and provides practical guidelines for managing adverse effects. In general, the most common adverse events associated with IFN beta therapy are flu-like symptoms, including fever, chills and myalgias, and headache. The flu-like symptoms typically resolve within 24 hours and may be mitigated by over-the-counter anti-inflammatory agents. Adverse events related to glatiramer acetate therapy include injection-site reactions and a systemic reaction consisting of flushing, chest tightness, palpitation, anxiety or dyspnoea. The systemic reaction is transient (30 seconds to 30 minutes) and self-limited. Mitoxantrone may cause nausea, vomiting, alopecia, amenorrhoea and myelosuppression; isolated cases of acute leukaemia and dose-related cardiotoxicity have been reported in the literature. Longer-term tolerability data on mitoxantrone as a treatment for multiple sclerosis are needed. It is important for physicians to counsel patients on DMA-related adverse effects, most of which are transient and of mild-to-moderate severity. Various strategies that can be employed to prevent or manage these adverse effects and lessen their impact on the patient are discussed.
ACCESSION #
16283546

 

Related Articles

  • Multiple sclerosis. Gaze, Harriet // BMJ: British Medical Journal (International Edition);6/14/2003, Vol. 326 Issue 7402, p1323 

    Presents Harriet Gaze, a journalist who has multiple sclerosis (MS), as she talks to former general practitioner Stephen Hempling, who had MS diagnosed at age 50. Belief that Hempling probably has better medical care for his MS than she does for hers; Hemplings' current forensic career;...

  • Oxidative Stress in Patients with Multiple Sclerosis on Interferon Therapy. Abdullah, Kassim Salih; Majdal, Hakki Mohammed; Mohamad, Marwan // Tikrit Medical Journal;2012, Vol. 18 Issue 2, p9 

    Controlled comparative clinical trial, conducted on the department of neurology , Ibin Sina teaching hospital, Mosul -Iraq, to evaluate the oxidative stress status in patient with multiple sclerosis. Thirty female patients diagnosed as multiple sclerosis enrolled in the study, thirty healthy...

  • Epidemiology of frequent attenders: a 3-year historic cohort study comparing attendance, morbidity and prescriptions of one-year and persistent frequent attenders. Smits, Frans ThM.; Brouwer, Henk J.; ter Riet, Gerben; van Weert, Henk C. P. // BMC Public Health;2009, Vol. 9 Issue 1, p1 

    Background: General Practitioners spend a disproportionate amount of time on frequent attenders. So far, trials on the effect of interventions on frequent attenders have shown negative results. However, these trials were conducted in short-term frequent attenders. It would be more reasonable to...

  • Clinical trials in multiple sclerosis: Current and future requirements — potential pitfalls. Rieckmann, P. // Journal of Neurology;Dec2008 Supplement 6, Vol. 255, p66 

    Several lines of evidence support early immunomodulatory treatment of relapsing multiple sclerosis with either recombinant beta-interferons or glatiramer acetate and positive results from phase III trials encourage start of treatment even in patients with clinical isolated syndrome (CIS)....

  • Multiple Sclerosis News Headlines May 15, 2003 - June 14, 2003.  // PharmaWatch: CNS;July 2003, Vol. 2 Issue 7, p19 

    Reports developments on issues related to the treatment of multiple sclerosis as of July 2003. Details on the results of the first phase of the clinical trial of an interferon enhancing therapy conducted by Transition Therapeutics Inc.; Assessment on the efficacy of the Rebif drugs on patients...

  • Tissue viability and the inverse care law. White, Richard // Wounds UK;Nov2011, Vol. 7 Issue 4, p10 

    The author reflects on the standard of care for patients of all age groups with viability issues, who are being cared in their owned houses in England. The author states that general practitioners (GPs) are ignorant and indifferent on patient groups due to inadequate training and time-consuming...

  • Death waited eagerly for me. Farrell, Liam // GP: General Practitioner;10/27/2006, p20 

    The article presents the author's experience of visiting a patient at a ghostly house in the countryside. He was received by a skeletal figure. The patient said that he had a severe cough. The author examined him and found that he was suffering from viral fever. He suggested him to rest for some...

  • Spot(s). Robins, Bernard // Annals of Internal Medicine;4/19/2005, Vol. 142 Issue 8, p675 

    The article presents experience of the author as a doctor. The telephone call came from the answering service at noon on a hot Wednesday in July of 1957. The author had been in practice for about a month and was keeping busy making house calls for doctors on their days off or at night. This call...

  • The use of instrumental examinations in the diagnosis of headaches. Tynecka-Turowska, M.; Krasińska-Czerlunczakiewicz, H.; Mitosek-Szewczyk, K.; Stelmasiak, Z. // Neurological Sciences;Nov2003, Vol. 24 Issue 4, p305 

    Headaches are the most common complaint reported by patients to their physician. They can be divided into spontaneous and symptomatic. The findings of the history and examination may suggest the need for diagnostic testing. The ancillary investigation and management of headache is discussed.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics